Literature DB >> 11259367

Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3.

T M Watchorn1, I Waddell, N Dowidar, J A Ross.   

Abstract

A novel protein, proteolysis-inducing factor (PIF), has been isolated from the urine of patients with pancreatic cancer and is capable of inducing muscle proteolysis in vitro. Only adult skeletal muscle and liver exhibit substantial binding of PIF. We have investigated the effect of PIF on hepatic gene expression. Primary cultures of human hepatocytes and the human cell line HepG2 were incubated in the presence of PIF to assess its effects on hepatic transcription factors, proinflammatory cytokine production, and acute phase proteins. PIF activates both the transcription factors NF-kB and STAT3, which result in the increased production of IL-8, IL-6, and C-reactive protein and the decreased production of transferrin. The function of PIF, beyond muscle degradation, is unknown but here we show that it is involved in hepatic gene expression, and is thus likely to be involved in the proinflammatory response observed in cachexia. These results may also suggest a potential role for PIF during embryonic development. The expression of PIF peaks during the embryonic period E8 to E9, a stage that is crucial in the development of skeletal muscle and liver and during which both NF-kB and STAT3 activation can also be observed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259367     DOI: 10.1096/fj.00-0534fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  30 in total

Review 1.  Interleukin-6 and insulin sensitivity: friend or foe?

Authors:  A L Carey; M A Febbraio
Journal:  Diabetologia       Date:  2004-07-07       Impact factor: 10.122

Review 2.  For whom the bell tolls? DING proteins in health and disease.

Authors:  Anne Berna; François Bernier; Eric Chabrière; Mikael Elias; Ken Scott; Andrew Suh
Journal:  Cell Mol Life Sci       Date:  2009-03-17       Impact factor: 9.261

Review 3.  Targeting aldose reductase for the treatment of cancer.

Authors:  Ravinder Tammali; Satish K Srivastava; Kota V Ramana
Journal:  Curr Cancer Drug Targets       Date:  2011-06       Impact factor: 3.428

Review 4.  STAT3 in the systemic inflammation of cancer cachexia.

Authors:  Teresa A Zimmers; Melissa L Fishel; Andrea Bonetto
Journal:  Semin Cell Dev Biol       Date:  2016-02-06       Impact factor: 7.727

5.  Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3.

Authors:  Alok Agrawal; Hyunjoo Cha-Molstad; David Samols; Irving Kushner
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

Review 6.  Animal models of the cancer anorexia-cachexia syndrome.

Authors:  Nabila Bennani-Baiti; Declan Walsh
Journal:  Support Care Cancer       Date:  2010-08-17       Impact factor: 3.603

Review 7.  Cachexia in patients with oesophageal cancer.

Authors:  Poorna Anandavadivelan; Pernilla Lagergren
Journal:  Nat Rev Clin Oncol       Date:  2015-11-17       Impact factor: 66.675

8.  Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I.

Authors:  M A Spruit; R Gosselink; T Troosters; A Kasran; G Gayan-Ramirez; P Bogaerts; R Bouillon; M Decramer
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

9.  The survival-promoting peptide Y-P30 enhances binding of pleiotrophin to syndecan-2 and -3 and supports its neuritogenic activity.

Authors:  Peter Landgraf; Petra Wahle; Hans-Christian Pape; Eckart D Gundelfinger; Michael R Kreutz
Journal:  J Biol Chem       Date:  2008-07-03       Impact factor: 5.157

Review 10.  Cancer cachexia.

Authors:  Michael J Tisdale
Journal:  Langenbecks Arch Surg       Date:  2004-05-28       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.